Loading…
NatureLab Corp. received a warning letter for manufacturing adulterated dietary supplements in violation of Current Good Manufacturing Practice (CGMP) regulations. During follow-up inspections in October 2021, the FDA identified serious violations including the company's failure to establish required specifications for critical control points in the manufacturing process and inability to ensure consistent production of its products. Specifically, NatureLab failed to establish proper identity specifications for components used in manufacturing its dietary supplements, as required by 21 CFR 111.70(a). These deficiencies rendered the company's dietary supplements non-compliant with federal manufacturing standards.